A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis
Latest Information Update: 07 May 2024
Price :
$35 *
At a glance
- Drugs Calcifediol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors OPKO Health
- 07 May 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May 2022).
- 04 Mar 2021 Planned End Date changed from 15 Feb 2021 to 31 Mar 2023.
- 04 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Mar 2023.